期刊
DRUG RESISTANCE UPDATES
卷 33-35, 期 -, 页码 1-22出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2017.10.002
关键词
Antimicrobial blue light; Non-antibiotic approach; Endogenous photosensitizer; Antibiotic resistance; Microbe; Bacterium; Fungus; Infection
资金
- National Institute of Health [R21AI109172, R01AI123312]
- Department of Defense [FA9550-16-1-0479, FA9550-17-1-0277]
- Center for Integration of Medicine and Innovative Technology [13-1021, 13-1033, 14-1894]
- Airlift Research Foundation [109421]
- American Society for Laser Medicine Surgery [BS.F04.14]
- Orthopaedic Trauma Association [16, 181]
- Executive Committee On Research at Massachusetts General Hospital
- Smith Infectious Diseases Foundation
- ASLMS [BS.S02.15]
As an innovative non-antibiotic approach, antimicrobial blue light in the spectrum of 400-470 run has demonstrated its intrinsic antimicrobial properties resulting from the presence of endogenous photosensitizing chromophores in pathogenic microbes and, subsequently, its promise as a counteracter of antibiotic resistance. Since we published our last review of antimicrobial blue light in 2012, there have been a substantial number of new studies reported in this area. Here we provide an updated overview of the findings from the new studies over the past 5 years, including the efficacy of antimicrobial blue light inactivation of different microbes, its mechanism of action, synergism of antimicrobial blue light with other angents, its effect on host cells and tissues, the potential development of resistance to antimicrobial blue light by microbes, and a novel interstitial delivery approach of antimicrobial blue light. The potential new applications of antimicrobial blue light are also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据